Letter: hepatic steatosis in chronic hepatitis B-viral, metabolic or treatment-related?
- PMID: 34907566
- DOI: 10.1111/apt.16687
Letter: hepatic steatosis in chronic hepatitis B-viral, metabolic or treatment-related?
Comment in
-
Letter: hepatic steatosis in chronic hepatitis B-viral, metabolic or treatment-related? Authors' reply.Aliment Pharmacol Ther. 2022 Jan;55(1):149. doi: 10.1111/apt.16715. Aliment Pharmacol Ther. 2022. PMID: 34907560 No abstract available.
Comment on
-
Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B.Aliment Pharmacol Ther. 2021 Nov;54(9):1100-1109. doi: 10.1111/apt.16595. Epub 2021 Sep 1. Aliment Pharmacol Ther. 2021. PMID: 34469587
References
REFERENCES
-
- Zheng QI, Zou B, Wu Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther. 2021;54:1100-1109.
-
- Chang X-J, Shi Y-W, Wang J, et al. Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment. Hepatobiliary Pancreat Dis Int. 2021;20:416-425.
-
- Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56:1145-1151.
-
- Chang Y, Jung H-S, Cho J, et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am J Gastroenterol. 2016;111:1133-1140.
-
- Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46:716-723.